Nymox shareholders back full board slate 98%

NYMOX PHARMACEUTICAL CORP (NYMXF) reports the results of a shareholder vote held in August 2026 to elect its Board of Directors.

Rhea-AI Filing Summary

NYMOX PHARMACEUTICAL CORP (NYMXF) reports the results of a shareholder vote held in August 2026 to elect its Board of Directors. Shareholders elected Dr. Paul Averback (Chairman), Dr. David Morse, Dr. Russell Thomson, Dr. Kresimir Pucaj, and Robert Lachance.

Of 105,040,140 shares issued and outstanding, 47,885,624 shares (45.59%) were voted. The motion to elect directors received 47,066,029 shares (98.29%) in favor, 0 against, and 819,595 shares (1.71%) withheld/abstaining, with no spoiled ballots or non-votes. Voting by shareholders of record as of August 4, 2026 was closed and locked by Computershare on August 26, 2026 at 5:00 pm EST, and the nominees were declared duly elected at a virtual meeting on August 28, 2026.

Key Figures

Shares issued and outstanding: 105,040,140 shares Shares voted: 47,885,624 shares Voter participation: 45.59% +3 more

6 metrics

Shares issued and outstanding 105,040,140 shares Total shares issued and outstanding referenced for the August 2026 vote

Shares voted 47,885,624 shares Number of shares voted in the director election

Voter participation 45.59% Percentage of issued and outstanding shares that were voted

Votes in favor 47,066,029 shares (98.29%) Shares voting for the motion to elect directors

Withheld/abstaining votes 819,595 shares (1.71%) Shares withheld or abstaining on the motion to elect directors

Voting close time 5:00 pm EST on August 26, 2026 Time when voting was closed and locked by Computershare

Key Terms

foreign private issuer, Form 20-F, transfer agent, withheld/abstaining, +1 more

5 terms

foreign private issuer regulatory

"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

Form 20-F regulatory

"whether the registrant files or will file annual reports under cover of Form 20-F"

Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.

transfer agent financial

"The voting was closed and locked by the transfer agent (Computershare)"

A transfer agent is a financial service that keeps the official record of who owns a company's shares, handles the buying and selling of those shares on paper or electronically, and issues or cancels stock certificates. Think of it as the company’s records keeper and mailroom combined—investors rely on it to make sure dividends, shareholder mailings, ownership changes, and proxy voting are processed accurately and securely, which protects ownership rights and helps prevent errors or fraud.

withheld/abstaining financial

"819,595 shares (1.71%) withheld/abstaining, with no spoiled ballots"

virtual meeting other

"nominees were declared duly elected at the virtual meeting held 2 days"

FAQ

What did NYMXF shareholders approve in the August 2026 vote?

Shareholders approved the election of five directors: Dr. Paul Averback (Chairman), Dr. David Morse, Dr. Russell Thomson, Dr. Kresimir Pucaj, and Robert Lachance. The election motion was carried and the nominees were declared duly elected at a virtual meeting on August 28, 2026.

How many NYMXF shares were eligible and voted in the August 2026 meeting?

There were 105,040,140 shares issued and outstanding, all eligible. Of these, 47,885,624 shares were voted, representing 45.59% of the issued and outstanding shares based on the voting record.

What were the detailed voting results for NYMXF director elections in August 2026?

The motion to elect directors received 47,066,029 shares (98.29%) in favor, 0 shares against, and 819,595 shares (1.71%) withheld/abstaining. No spoiled ballots or non-votes were recorded according to the voting record.

Who was eligible to vote in NYMXF’s August 2026 director election?

Shareholders of NYMOX PHARMACEUTICAL CORP of record on August 4, 2026 were eligible to vote. Voting was conducted up to August 26, 2026 at 5:00 pm EST, when it was closed and locked by the transfer agent, Computershare.

When was the NYMXF shareholder meeting held and how was it conducted?

The special shareholders meeting at which the director election results were declared was held on August 28, 2026 as a virtual meeting. A transcript of this meeting is attached as Exhibit 99.1 to the report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/31/2026 - 12:21 PM Accepted by SEC EDGAR 08/31/2026 - 12:21 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of August, 2026

Commission File Number: 001-12033

Nymox Pharmaceutical Corporation

(Translation of registrant’s name into English)

Bay & Deveaux Streets, Nassau, The Bahamas 

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒     Form 40-F ☐

In shareholder voting concluded on 26 August, 2026, Nymox (the Company) shareholders voted in favor of the following members of the Board of Directors of the Company: Dr. Paul Averback, Chairman; Dr. David Morse; Dr. Russell Thomson; Dr. Kresimir Pucaj, Robert Lachance. Voters of record on August 4, 2026 were eligible to vote. The voting was closed and locked by the transfer agent (Computershare) on 26 August at 5:00 pm EST. Based on the voting record provided: of 105,040,140 total shares issued and outstanding, 47,885,624 shares (45.59%) were voted; the motion to elect directors received 47,066,029 shares (98.29%) in favor, 0 shares against, and 819,595 shares (1.71%) withheld/abstaining, with no spoiled ballots or non-votes recorded. The motion was carried and the nominees were declared duly elected at the virtual meeting held 2 days after the voting was closed and locked. The transcript from 28 August 2026 is attached in Exhibit 99.1.

EXHIBIT INDEX

Exhibit No.		Description
99.1		Transcript of Special Shareholders Meeting, dated August 28, 2026

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 31, 2026

	NYMOX PHARMACEUTICAL CORPORATION
	By:	/s/ Paul Averback
	Name:	Paul Averback
	Title:	President and Chief Executive Officer

3

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 TRANSCRIPT OF SPECIAL 8.5 KB